Literature DB >> 20811731

[Vascular dementia].

N Peters1, M Dichgans.   

Abstract

Vascular dementia (VaD) constitutes the second most frequent cause of dementia following Alzheimer's disease (AD). In contrast to AD, VaD encompasses a variety of conditions and dementia mechanisms including multiple and strategic infarcts, widespread white matter lesions and hemorrhages. The diagnosis of VaD is based on the patient history, the clinical evaluation and neuroimaging. Treatment of VaD should account for the underlying vascular condition and is directed towards the control of vascular risk factors and stroke prevention. The need for early diagnosis and preventive treatment has promoted the concept of vascular cognitive impairment (VCI). Harmonization standards for the description and study of VCI have recently been published. A common and distinct subtype of VaD is subcortical ischemic vascular dementia (SIVD) which is related to cerebral small vessel disease. SIVD is clinically characterized by impairment of executive functions and processing speed with relatively preserved memory. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a genetic variant of SIVD, represents an important differential diagnosis and may serve as a model of SIVD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811731     DOI: 10.1007/s00115-009-2848-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  27 in total

1.  Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study.

Authors:  Markus Holtmannspötter; Nils Peters; Christian Opherk; Daniel Martin; Jürgen Herzog; Hartmut Brückmann; Philipp Sämann; Andreas Gschwendtner; Martin Dichgans
Journal:  Stroke       Date:  2005-11-03       Impact factor: 7.914

2.  MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL.

Authors:  M O'Sullivan; J M Jarosz; R J Martin; N Deasy; J F Powell; H S Markus
Journal:  Neurology       Date:  2001-03-13       Impact factor: 9.910

3.  Islington study of dementia subtypes in the community.

Authors:  Tim Stevens; Gill Livingston; Ginnette Kitchen; Monica Manela; Zuzana Walker; Cornelius Katona
Journal:  Br J Psychiatry       Date:  2002-03       Impact factor: 9.319

4.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

5.  Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies.

Authors:  A J Mitchell; M Shiri-Feshki
Journal:  Acta Psychiatr Scand       Date:  2008-02-18       Impact factor: 6.392

6.  Patterns of MRI lesions in CADASIL.

Authors:  H Chabriat; C Levy; H Taillia; M T Iba-Zizen; K Vahedi; A Joutel; E Tournier-Lasserve; M G Bousser
Journal:  Neurology       Date:  1998-08       Impact factor: 9.910

7.  Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.

Authors:  Martin Dichgans; Hugh S Markus; Stephen Salloway; Auli Verkkoniemi; Margaret Moline; Qin Wang; Holly Posner; Hugues S Chabriat
Journal:  Lancet Neurol       Date:  2008-02-28       Impact factor: 44.182

8.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

9.  A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials.

Authors:  Nils Peters; Jürgen Herzog; Christian Opherk; Martin Dichgans
Journal:  Stroke       Date:  2004-05-20       Impact factor: 7.914

10.  Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer's Disease.

Authors:  A Heyman; G G Fillenbaum; K A Welsh-Bohmer; M Gearing; S S Mirra; R C Mohs; B L Peterson; C F Pieper
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

View more
  2 in total

1.  [Symptoms and imaging diagnostics of neurodegenerative dementia].

Authors:  P Schönknecht; C Sattler; P Toro; M Essig
Journal:  Radiologe       Date:  2011-04       Impact factor: 0.635

2.  Cognitive syndromes after the first stroke.

Authors:  Denisa Salihović; Dževdet Smajlović; Milija Mijajlović; Emina Zoletić; Omer Ć Ibrahimagić
Journal:  Neurol Sci       Date:  2018-05-19       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.